N/A N=216 Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment
Nasal Carriers of Staphylococcus Aureus
Primary: Carrier Rate for Staphylococcus Aureus — 20.8 percentage of subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=39 Reduction of Staph Aureus Carriage by Non-Antibiotic NOZIN® Nasal Sanitizer® Antiseptic
Infectious Disease
Primary: Treatment-associated Change in S. Aureus Colonization During a Typical 10-hour Work Day — -99.8; -13.5 Percent change in colonization — p=<0.01
Phase 4 N=110 S. Aureus Screening and Decolonization
Wound Infection Due to Staphylococcus Aureus · MRSA Infection of Postoperative Wound
Primary: Eradication of Staphylococcus Aureus (SA) Carriage at All 4 Body Sites Tested. — 13; 41 Participants
Phase 2 N=57 Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus
Infections, Bacterial
Primary: Plasma Retapumulin Pharmacokinetic Parameters by Treatment at Days 1 and 3 Evaluated by Plasma AUC After Dosing — 0.8663; 0.3816; 4.2802; 2.0881 ng.h /mL
Phase 4 N=12 Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)
Staphylococcal Infection
Primary: Apparent Eradication of Nasal Carriage of SA — 9 participants
N/A N=463 A Novel Approach to Methicillin-resistant Staphylococcus Aureus (MRSA) Screening of Colonized Patients
MRSA Colonization
Primary: Number of Subjects With Single Negative Polymerase Chain Reaction (PCR) Result and 3 Negative Culture Assays — 96.6 percentage of participants
N/A N=9,707 Nasopharyngeal Streptococcus Pneumoniae Carriage
Streptococcus Pneumoniae Infections
Primary: Percentage of Participants With Carriage of Streptococcus Pneumoniae in Nasopharynx — 12.6 Percentage of Participants
Phase 4 N=192 Povidone-Iodine for Nasal Decolonization
Surgical Wound Infection · Preoperative Care · Methicillin-Resistant Staphylococcus Aureus
Primary: Change in S. Aureus/MRSA Colony Forming Units (CFU) in Nasal Swab Specimen After Treatment in Patients Who Presented With a Positive for S. Aureus/MRSA…
Phase 2 N=63 Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects
Staphylococcus Aureus Infection
Primary: Apparent Eradication of Nasal SA After the Last Dose of XF-73 Based on Semi-quantitative SA Scores From a Broth Enrichment Method. — 3; 1; 4 participants — p=0.792
Phase 4 N=53 Retapamulin for Reducing MRSA Nasal Carriage
Methicillin-Resistant Staphylococcus Aureus
Primary: Proportion of Participants With MRSA Clearance — 8; 4 Participants — p=0.320
Phase 4 N=28 Cultures Before and After Decolonization in Community Dwelling Adults With Current S. Aureus Colonization
Human Microbiome
Primary: Change in the Abundance of Staphylococcus Aureus in the Nose After Decolonization — -781 fg/uL
N/A N=183 Staphylococcus Aureus Decolonization Study
Staphylococcal Skin Infections · Abscesses · Furunculosis
Primary: Number of Index Patients Eradicated of S. Aureus Carriage - 1 Month After Performing Decolonization Measures — 39; 35 Participants — p=1.00
Phase 2 N=67 Decolonization of the Oropharynx, an Important and Neglected Reservoir of S. Aureus Colonization
S. Aureus Oropharyngeal Colonization
Primary: Number of Participants With Eradiction of S. Aureus From the Oropharyngeal at 7 Days — 18; 7 Participants
Phase 4 N=18 Stop Community MRSA Colonization Among Patients
MRSA
Primary: Number of Participants With Recurrent Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization — 2; 3 Participants
Phase 4 N=31 The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis
Atopic Dermatitis
Primary: Change in Eczema Area and Severity Index (EASI)Scores According to Location — -1.06; -0.57; -4.94; -0.88 Change in EASI Score
N/A N=300 The Natural History of Community-Associated MRSA Infections and Decolonization Strategies
Abscesses · Furunculosis · Staphylococcus Aureus
Primary: Number of Participants Eradicated of S. Aureus Carriage - 1 Month After Intervention — 24; 35; 35; 34 Participants
N/A N=3,641 Prevalence of Nasopharyngeal Carriage of Streptococcus Pneumoniae in Healthy Children of 12-18 Months in 6 Cities, China
Streptococcus Pneumoniae Infections
Primary: Percentage of Participants With Nasopharyngeal Carriage of Streptococcus Pneumoniae — 12.5; 7.2; 16.6; 9.3 percentage of participants
N/A N=60 Treatment of Staphylococcus Aureus Colonization in Hand Eczema
Hand Eczema · Foot Eczema
Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035
Phase 3 N=47 Retapamulin as a Decolonizing Agent for MRSA
MRSA
Primary: Number of Participants With MRSA Carriage at 1 Week Post Decolonization With Retapamulin or Placebo — 2; 13 Participants — p=0.0004
Phase 4 N=1,697 Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin
Surgical Site Infection
Primary: Surgical Site Infections Occurring Within 12 Months of Surgical Procedure — 0; 5 participants
Phase 2 N=124 Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection
Staphylococcal Infections · Surgical Site Infection
Primary: Change in S. Aureus Log CFU/mL From Baseline to Pre-surgery — -2.842; -0.469 log10 (CFU/mL)
Phase 4 N=50 Evaluation of a Staphylococcus Eradication Protocol for Patients Who Present to the ED With Cutaneous Abscess
Cutaneous Abscess
Primary: Recurrence of Cutaneous Abscess — 5; 7 Participants
N/A N=307 Treating Parents to Reduce NICU Transmission of Staphylococcus Aureus Trial
Staph Aureus Colonization · Staph Aureus Infection
Primary: Number of Neonatal Infections With a S. Aureus Strain That is Concordant to Parental S. Aureus Strain — 13; 29 neonatal S. aureus infections
N/A N=550 Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons
HIV Infections · Staphylococcal Infections
Primary: The Presence of MRSA on Repeated Swabs to Assess the Efficacy of These Medications on Clearing MRSA Colonization — 12; 14; 0 Participants
N/A N=474 Individualized vs. Household MRSA Decolonization
Staphylococcal Skin Infection · Abscess · Furunculosis
Primary: Number of Participants With Incidence of SSTI at 3 Months After Decolonization — 23; 23 Participants — p=0.757
N/A N=987 Prevention of Recurrent Infections Caused by Community Acquired Staphylococcus Aureus (CA-SA) in Children
Community-Acquired Staphylococcus Aureus
Primary: Medically Attended Skin and Soft Tissue Infections (MA-SSI) — 20.9; 17 percentage of partipants
Phase 2 N=5 Nasal Tea Tree Oil for the Prevention of Infections in PD Patients
End Stage Renal Failure on Dialysis
Primary: Primary Endpoint Will be the Number of Tea Tree Oil Patients That Did Not Have a Catheter-related Infection Within 6 Months After Entry Into the Trial. — 0 participants
Phase 2 N=155 Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants
Staphylococcal Infection
Primary: Number of Participants With Solicited Adverse Events (AEs) During Days 1-7 — 2; 1; 17; 4 participants
Phase 4 N=65 Nasal Decolonization for Orthopedic Trauma Patients
Surgical Site Infection
Primary: Number of Participants With Staphylococcus Aureus Nasal Colonization — 12 Participants
N/A N=223 Epidemiology and Prevention of Methicillin Resistant Staphylococcus Aureus (MRSA) Transmission in the Community
MRSA - Methicillin Resistant Staphylococcus Aureus Infection
Primary: Recurrent Infection — 1; 3; 1 participants